Albireo Pharma 2017 BIO CEO Investor Conference Presentation

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Albireo Pharma presents its portfolio of bile acid modulators for orphan pediatric liver diseases at the BIO CEO & Investor Conference. The company highlights its lead candidate A4250 in development for Progressive Familial Intrahepatic Cholestasis (PFIC) and chronic cholestasis, along with partnered asset elobixibat.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Albireo Pharma

View all →

presentation

presentation

Similar investor_presentations from other companies

Browse all →

Lipella Pharmaceuticals Clinical Stage Biotech - Serious Diseases

investor_presentation

22 Pages

Lipella Pharmaceuticals Inc.

Snow Lake Lithium LITM 2023 Investor Presentation

investor_presentation